Pe­ter Thiel jumps aboard Al­loy's lat­est $75M round, adding some heft to the an­ti­body dis­cov­ery out­fit's nascent plat­form

In the world of ven­ture cap­i­tal, names mat­ter — and few names are big­ger than Sil­i­con Val­ley pow­er play­er Pe­ter Thiel. Af­ter mak­ing a sprin­kling of plays over the past cou­ple years, Thiel is now putting his weighty name be­hind an­ti­body play­er Al­loy Ther­a­peu­tics as part of a new fundrais­ing round.

Boston-based Al­loy, which was found­ed in 2017, closed a $75 mil­lion Se­ries C on Mon­day, head­lined by Thiel’s in­vest­ment. The biotech is build­ing a hu­man an­ti­body dis­cov­ery plat­form, dubbed ATX-Gx, that us­es high­ly im­muno­com­pe­tent trans­genic mice strains.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER